Capsazepine

Catalog No.S8137

For research use only.

Capsazepine acts as a competitive antagonist of capsaicin and a transient receptor potential vanilloid type 1(TRPV1) antagonist.

Capsazepine Chemical Structure

CAS No. 138977-28-3

Selleck's Capsazepine has been cited by 5 Publications

Purity & Quality Control

Choose Selective TRP Channel Inhibitors

Biological Activity

Description Capsazepine acts as a competitive antagonist of capsaicin and a transient receptor potential vanilloid type 1(TRPV1) antagonist.
Targets
TRPV1 [2] Na,K-ATPase [3]
12 μM(EC50)
In vitro

Capsazepine(CPZ) at a concentration of 94.2 µg/ml (IC50 concentration of capsazepine) exhibits a statistically significant inhibition of osteoclast growth and proliferation[2]. Capsazepine converts the NKA into Na-ATPase. CPZ inhibits K+-dependent activity but allows Na-ATPase associated with Na+ transport. CPZ has no effect on Na-ATPase measured in the absence of K+. CPZ also inhibits para-nitrophenyl phosphatase activity, albeit with a lower affinity. CPZ strongly reduces the steady-state EP level and the Na+ affinity for phosphorylation decreased 3-fold after CPZ treatment. In summary, CPZ blocks an Na+/K+ cycle in the NKA but leaves an Na+ cycle intact, reducing the transport stoichiometry of the pump[3]. Capsazepine inhibits osteoclast formation and bone resorption in a dose dependent manner in bone marrow-osteoblast co-cultures and RANKL generated osteoclast cultures. Capsazepine also suppresses RANKL induced IκB and ERK1/2 phosphorylation and causes apoptosis of mature osteoclasts and also inhibits alkaline phosphatase activity and bone nodule formation in calvarial osteoblast cultures[4].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO NGfsfVZHfW6ldHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKGOjcIPhbYNqdi2rbnT1Z4VlKFuFYUKrYUB2eHSja3WgZpkhWmG2IG\hcoltdG:rZDDy[YNmeHSxcjCxJEhXWjFrIHX4dJJme3OrbnegR2hQKGOnbHzzMEBMcT1yLkWy{txO MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjh{NUm1NEc,OTJ6MkW5OVA9N2F-
CHO MWHGeY5kfGmxbjDhd5NigQ>? NEWzUI1KdmirYnn0bY9vKG:oIHPhdJNicWOrbj3pcoR2[2WmIHPhcINqfW1idYD0ZYtmKGK7IITyZY5{cWWwdDDy[YNmeHSxcjDwc5RmdnSrYXygeoFvcWyub3nkJJR6eGViMTDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{NCCLQ{WwQVAvPDMQvF2= MoHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4M{SwNFIoRjF3NkO0NFAzRC:jPh?=
CHO NIqz[5BHfW6ldHnvckBie3OjeR?= MmLORY51[WexbnnzeEBi[3Srdnn0fUB1d3ejcnTzJJJifCCWUmDWNUBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|LDDLbV0xNjV{zszN NGf2enU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm5N|A3Oyd-MUW5PVMxPjN:L3G+
CHO NVLpcYxmTnWwY4Tpc44h[XO|YYm= NITqcGNKdiC4aYTyc{BqdmirYnn0bY9vKG:oIGuzTH1TXFhiYnnu[Ilv\yC2bzDyZZQhXFKSVkGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyxiS3m9NU4{|ryP NFfQc|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm5N|A3Oyd-MUW5PVMxPjN:L3G+
HEK293 NV;GZXpGTnWwY4Tpc44h[XO|YYm= NUS4TFVkUW6qaXLpeIlwdiCxZjCxNFAhdk1iY3Hwd4Fq[2mwIHXm[oVkfCCxbjDpcpRz[WOnbHz1cIFzKFuFYUKrYUBkd26lZX70doF1cW:wIHnuJGhGUzJ7MzDj[YxteyCneIDy[ZN{cW6pIHj1cYFvKFSUUG[xMEBKSzVyPUCuNFU3Os7:TR?= Mn24QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZyMECwNFIoRjF4MECwNFAzRC:jPh?=
CHO M33keWZ2dmO2aX;uJIF{e2G7 NWTE[WNzSW62YXfvcol{fCCjY4Tpeol1gSCob4KgdoF1KFSUUG[xJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNuIFvpQVAvPTMQvF2= NGP3VHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkCwOVIyPSd-MU[wNFUzOTV:L3G+
CHO MnTYSpVv[3Srb36gZZN{[Xl? NIW2dmVKdiC4aYTyc{BjcW6maX7nJIFn\mmwaYT5JIZweiC{YYSgWHJRXjFiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{B2e2mwZzDbN2heNVKWWDygT4k:OS5|zszN M3nrXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4MEC1NlE2Lz5zNkCwOVIyPTxxYU6=
human TRPV1 expressing cells NY\vV3Q5TnWwY4Tpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGOjbHPpeY0hcW6obIX4JIV3d2unZDDifUBk[XC|YXnjbY4hcW5iaIXtZY4hXFKSVkGg[ZhxemW|c3nu[{Bk\WyuczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUC9NE4{OzUQvF2= M2j6Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEKwNFM1Lz5zNkSyNFA{PDxxYU6=
CHO NWnGOIYzTnWwY4Tpc44h[XO|YYm= MkHIRY51[WexbnnzeEBi[3Srdnn0fUBifCC{YYSgWHJRXjFiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINidGOrdX2geZB1[WunLDDLbV0xNjV{zszN Ml7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyM{WwNVMoRjF5MEO1NFE{RC:jPh?=
CHO NIGwd2RHfW6ldHnvckBie3OjeR?= NWXoW45LTGm|cHzhZ4Vu\W62IH;mJHs{UF2UVGig[pJwdSC{YYSgWHJRXjFiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{whU2l;MT6z{txO NGLNUlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{CzOVAyOyd-MUewN|UxOTN:L3G+
CHO Mny2SpVv[3Srb36gZZN{[Xl? MnXRRY51[WexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVWlCYMTDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHLsc4Ns[WSnIH;mJINieHOjaXPpck1qdmS3Y3XkJJJm[2WydH;yJIFkfGm4YYTpc44h[nliYXXxeY9zcW5iYnHz[YQh[XO|YYmsJGlEPTB;MD6wN|nPxE1? MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OEm1O|AoRjF5NEi5OVcxRC:jPh?=
CHO MVTGeY5kfGmxbjDhd5NigQ>? M2[2bGFvfGGpb37pd5Qh[WO2aY\peJkh[XRiaIXtZY4hXFKSVkGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDicI9kc2GmZTDv[kBk[XC|YXnjbY4ucW6mdXPl[EBz\WOncITvdkBi[3SrdnH0bY9vKGK7IGu0OWNiOiufIIXweIFs\SCjc4PhfUwhUUN3ME2wMlA2O87:TR?= NHzQSGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S4PVU4OCd-MUe0PFk2PzB:L3G+
CHO NHvsSJZHfW6ldHnvckBie3OjeR?= NX\Tc5VoSW62YXfvcol{fCCjY4Tpeol1gSCjdDDoeY1idiCWUmDWNUBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIJtd2OtYXTlJI9nKGGlaXStbY5lfWOnZDDy[YNmeHSxcjDhZ5RqfmG2aX;uJIJ6KFt2NVPhNkteKHWydHHr[UBie3OjeTygTWM2OD1yLkC2Pe69VQ>? NHLmbY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S4PVU4OCd-MUe0PFk2PzB:L3G+
CHO NIDCbpBHfW6ldHnvckBie3OjeR?= M4fhfGFvfGGpb37pd5Qh[WO2aY\peJkh[XRicnH0JHRTWFZzIHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiYnzvZ4ti\GVib3[gZ4Fxe2GrY3nuMYlv\HWlZXSgdoVk\XC2b4KgZYN1cX[jdHnvckBjgSCjZYH1c5JqdiCkYYPl[EBie3OjeTygTWM2OD1yLkKy{txO MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR6OUW3NEc,OTd2OEm1O|A9N2F-
CHO MWHGeY5kfGmxbjDhd5NigQ>? M{f0[2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiaIXtZY4hXFKSVkGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDicI9kc2GmZTDv[kBi[2mmLXnu[JVk\WRicnXj[ZB1d3JiYXP0bZZifGmxbjDifUBi\XG3b4LpckBj[XOnZDDhd5NigSxiSVO1NF0xNjN{zszN MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR6OUW3NEc,OTd2OEm1O|A9N2F-
CHO MX3GeY5kfGmxbjDhd5NigQ>? MUDBcpRi\2:waYP0JIFkfGm4aYT5JIF1KHKjdDDUVnBXOSCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIF{e2W|c3XkJIF{KGKub3PrZYRmKG:oIHPhdJNicWOrbj3pcoR2[2WmIILlZ4VxfG:{IHHjeIl3[XSrb36gZpkhYzR3Q3GyL30hfXC2YXvlJIF{e2G7LDDJR|UxRTBwOEi3{txO MonuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OEm1O|AoRjF5NEi5OVcxRC:jPh?=
CHO NWDIbXpITnWwY4Tpc44h[XO|YYm= M4K3UmFvfGGpb37pd5Qh[WO2aY\peJkh[XRicnH0JHRTWFZzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiY3HsZ4l2dSB2NTD1dJRic2VuIFvpQVAvPTMQvF2= MlfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyN{K3NlAoRjF6MEeyO|IxRC:jPh?=
CHO NWrwb2hzTnWwY4Tpc44h[XO|YYm= NXfYPVkxTGm|cHzhZ4Vu\W62IH;mJHs{UF2UVGig[pJwdSC{YYSgWHJRXjFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{whU2l;MT6z{txO MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB5MkeyNEc,OThyN{K3NlA9N2F-
HEK293 NIn6SllHfW6ldHnvckBie3OjeR?= Mn\aRY51[WexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVWlCYMTDlfJBz\XO|ZXSgbY4hfGW2cnHjfYNtcW6nLYP0bY12dGG2ZXSgTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2Gyc3HpZ4lvNWmwZIXj[YQhcW62cnHj[YxtfWyjcjDjZYxkcXWvIHzleoVteyCkeTDmcJVwemmvZYTybYMh[XO|YYmsJGVEPTB;Mj61NVE5Qc7:TR?= MmfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB|OEGzOlMoRjJyM{ixN|Y{RC:jPh?=
HEK293T MoHvSpVv[3Srb36gZZN{[Xl? Mn;nRY51[WexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBjemGrbjDUVnBXOSCneIDy[ZN{\WRiaX6gTGVMOjl|VDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEODUD3pcoR2[2WmIHnueJJi[2WubIXsZZIhS2F{KzDpcoZtfXhiYomg[ox2d3Knc3PlcoNmNWKjc3XkJIF{e2G7LDDJR|UxRTBwMUZOwG0> Mlu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OESyOFAoRjJ2NEi0NlQxRC:jPh?=
HEK293T NFLlRYdHfW6ldHnvckBie3OjeR?= MWqxNEB2VQ>? NX\oXolZSW62YXfvcol{fCCjY4Tpeol1gSCjdDDoeY1idiCkcnHpckBVWlCYMTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIDyc5Rwdi2rbnT1Z4VlKGmwdILhZ4VtdHWuYYKgR4EzMyCrbn\seZgh[XRiMUCgeW0h[nliZnz1c5Jme2OnbnPlMYJie2WmIHHzd4F6 NUHtdms4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFQzPDBpPkK0OFg1OjRyPD;hQi=>
HEK T-REx cells M3z2dGZ2dmO2aX;uJIF{e2G7 NE\kPW0,PTBidV2= NH[z[XhCdnSjZ3;ubZN1KGG2IGTSVG05KGm|b3zheIVlKG[{b32gcY92e2ViZH;yd4FtKHKxb4Sg[4Fv\2yrb36gZ4VtdHNiZYjwdoV{e2WmIHnuJGhGUyCWLWLFfEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHnjbYxqdi2rbnT1Z4VlKGmwdILhZ4VtdHWuYYKgR4EzMyCrbn\seZgh[XRiPkWwJJVOKGK7IH\seY9z\XOlZX7j[U1j[XOnZDDhd5NigQ>? MlXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OESyOFAoRjJ2NEi0NlQxRC:jPh?=
HEK293T MW\GeY5kfGmxbjDhd5NigQ>? MlLNNVAxKHWP NH;yR5RCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHj1cYFvKGK{YXnuJHRTWFZzIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicILveI9vNWmwZIXj[YQhcW62cnHj[YxtfWyjcjDDZVIsKGmwZnz1fEBifCBzMECgeW0h[nliZnz1c5Jme2OnbnPlMYJie2WmIHHzd4F6 NV;1O|JsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFQzPDBpPkK0OFg1OjRyPD;hQi=>
T-REx HEK cells NED0VJNHfW6ldHnvckBie3OjeR?= M{D6UFMhdWmwcx?= NVvqbYlOSW62YXfvcol{fCCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHRTWFZzIHX4dJJme3OnZDDpckBVNVKHeDDISWsh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDjZZB{[WmlaX6tbY5lfWOnZDDpcoNz\WG|ZTDpckBqdnS{YXPlcIx2dGG{IFPhNksh[WOldX31cIF1cW:wIIDy[U1qdmO3YnH0[YQh\m:{IEOgcYlveyCycnnvdkB1dyClYYDzZYlkcW5ic4TpcZVt[XSrb36gZpkhTmy3bz20JGFOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVA:OC5yNklOwG0> M1uwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWyNlA3Lz5{NUC1NlIxPjxxYU6=
T-REx HEK cells M3L4cmZ2dmO2aX;uJIF{e2G7 MmfqN{BucW6| NHTGTG1CdnSjZ3;ubZN1KGGldHn2bZR6KGGpYXnud5QhdW:3c3WgWHJRVThiZYjwdoV{e2WmIHnuJHQuWkW6IFjFT{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPvcIQucW6mdXPl[EBqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJGNiOitiYXPjeY12dGG2aX;uJJBz\S2rbnP1ZoF1\WRiZn;yJFMhdWmwczDwdolweiC2bzDjc4xlKHO2aX31cIF1cW:wIHL5JGZtfW9vNDDBUUBlgWViYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6 MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MkKwOkc,OjVyNUKyNFY9N2F-
HeLa Mmr1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MX6yOEBpenN? NGDCc5lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IHPlcIwhfGm2ZYKgPVYh[XG3ZX;1d{Bvd25vcnHkbY9i[3SrdnWgZ4VtdCCycn;sbYZmemG2aX;uJIF{e2G7LDDJR|UxRTNyzszN MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV{OEG2Nkc,OzB3MkixOlI9N2F-
In vivo In mice, the TRPV1 antagonist capsazepine blocks morphine tolerance and dependence in mice. Acute capsazepine treatment (5 mg/kg, i.p.) potentiates the antinociceptive effects of morphine, as measured by the hot-plate test. Repeated co-treatment of capsazepine (2.5 mg/kg, i.p.) with morphine attenuates the development of tolerance to the antinociceptive effect of morphine. The development of morphine dependence is also reduced by capsazepine (1.25 or 2.5 mg/kg, i.p.)[1]. Capsazepine (1 mg/kg/day) inhibits ovariectomy induced bone loss in mice and histomorphometric analysis shows inhibitory effects on indices of bone resorption and bone formation[4].

Protocol (from reference)

Cell Research:[2]
  • Cell lines: Murine macrophage cell line RAW 264.7
  • Concentrations: 94.2 µg/ml
  • Incubation Time: 72 h
  • Method: The cells are plated and treated with different concentrations of the test compounds and allowed to proliferate for 72 h. After 72 h of proliferation the cells are fixed in 10% formalin saline (50 μl/well) for 30 min. Then the cells are stained with crystal violet (0.05% w/v) for 30 min. The wells are then washed thoroughly with distilled water to remove any unbound dye and destained with Sorenson's buffer (0.1 M sodium citrate in 50% ethanol, pH 4.2). The absorbance of the extracted stain is measured at 540 nm.
Animal Research:[1]
  • Animal Models: Institute of Cancer Research mice(ICR mice)
  • Dosages: 1.25, 2.5, or 5 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 376.90
Formula

C19H21ClN2O2S

CAS No. 138977-28-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CC2=CC(=C(C=C2CN(C1)C(=S)NCCC3=CC=C(C=C3)Cl)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Capsazepine | Capsazepine supplier | purchase Capsazepine | Capsazepine cost | Capsazepine manufacturer | order Capsazepine | Capsazepine distributor